Q-omics provides the consensus-scored PXT1 profile across patient tissues and cancer cell-line models. PXT1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PXT1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PXT1 RNA expression shows 15,097 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, KICH, and UVM as cancer lineages where PXT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PXT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PXT1 survival associations across molecular data types. PXT1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PXT1 RNA expression–survival associations across cancer types. High PXT1 expression shows unfavorable associations in BRCA and KIRC, but favorable associations in UCS, CESC, SCLC and LUAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for PXT1 RNA expression.
This table summarizes PXT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PXT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PXT1 shows lower tumor expression in KICH, PAAD and THCA and higher tumor expression in STAD, BRCA and LIHC. The KICH box plot shows higher PXT1 RNA expression in normal versus tumor tissue (log2 FC = −0.134, t-test p < 0.001).
This table shows molecular features associated with PXT1 in patient tissues and cancer cell lines. In patient samples, PXT1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PXT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and OESOPHAGUS.
